A Fresh Look At Syndax Pharmaceuticals

Syndax Pharma outlook: Revuforj first-mover edge, pipeline catalysts (Niktimvo), and profitability path amid misses. Click here to read more about SNDX.

Syndax Pharmaceuticals, Inc. (SNDX) is leveraging its broad label approval and first-mover advantage with acute leukemia therapy Revuforj to approach profitability while attempting to advance it to a frontline (1L) setting. Data from Niktimvo’s 1L chronic Summary - Syndax Pharmaceuticals is leveraging first-mover advantage and broad label approval for Revuforj to approach profitability despite recent revenue misses. - SNDX's near-term catalysts include pivotal Phase 2/3 data for Niktimvo in 1L cGvHD and IPF, expected in 4Q26 and 2H26, respectively.

- Sell-side consensus remains bullish unaminous buy ratings from the analyst firm community which forecasts profitability in FY2028 and significant revenue growth from pipeline expansion. - A fresh analysis on this small cap oncology concern follows in the paragraphs below.

- Looking for a helping hand in the market? Members of The Biotech Forum get exclusive ideas and guidance to navigate any climate. Learn More » Analyst’s Disclosure: I/we have a beneficial long position in the shares of KURA, MESO, SNDX either through stock ownership, options, or other derivatives.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.